INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
Public company

DBVTDBV Technologies S.A.

CIK 0001613780

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 2
Max Insider Score31
Connections5with evidence

DBVT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
31
MP
Mohideen PharisChief Medical Officer
DBVTDBV Technologies S.A.
Open-market sale
SELL$19K
6,496 sh
Nov 20, 2025Nov 25, 2025
traded Nov 20, 2025
+5dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Lobbied forevidence
    WINNING STRATEGIES WASHINGTONLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Mohideen PharisChief Medical Officer · Nov 25, 2025
  • ← Insider ofevidence
    Trapp Kevin MichaelChief Commercial Officer · Nov 24, 2025
17
MP
Mohideen PharisChief Medical Officer
DBVTDBV Technologies S.A.
Open-market sale
SELL
$4,498
1,624 sh
Nov 21, 2025
Nov 25, 2025
traded Nov 21, 2025
+4d
SEC FORM 4

Evidence

13
MP
Mohideen PharisChief Medical Officer
DBVTDBV Technologies S.A.
Grant or award
A—
44.0K sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

5
MP
Mohideen PharisChief Medical Officer
DBVTDBV Technologies S.A.
Grant or award
A—
253.0K sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

9
TM
Trapp Kevin MichaelChief Commercial Officer
DBVTDBV Technologies S.A.
Grant or award
A—
316.3K sh
Nov 21, 2025Nov 24, 2025
traded Nov 21, 2025
+3dSEC FORM 4

Evidence

21
BV
Boucinha VirginieChief Financial Officer
DBVTDBV Technologies S.A.
Grant or award
A—
32.0K sh
Nov 21, 2025Nov 24, 2025
traded Nov 21, 2025
+3dSEC FORM 4

Evidence

9
BV
Boucinha VirginieChief Financial Officer
DBVTDBV Technologies S.A.
Grant or award
A—
192.0K sh
Nov 21, 2025Nov 24, 2025
traded Nov 21, 2025
+3dSEC FORM 4

Evidence

9
TM
Trapp Kevin MichaelChief Commercial Officer
DBVTDBV Technologies S.A.
Grant or award
A—
55.0K sh
Nov 21, 2025Nov 24, 2025
traded Nov 21, 2025
+3dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Boucinha VirginieChief Financial Officer · Nov 24, 2025

    • Lobbying

    $60K reported · de-duplicated
    2026 Q2 $30K via firms2026 Q1 $30K via firms
    • WINNING STRATEGIES WASHINGTON$30K2026 Q2 · posted Aug 26, 2026 · Health issues
    • WINNING STRATEGIES WASHINGTON$30K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.